Cancer – AINV18P1: Phase 1 Study of Palbociclib, A CDK 4/6 Inhibitor, in Combination with Chemotherapy in Children with Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Condition or Therapy:
B- or T-lineage Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
What is the goal of this study?
The goal of this study is to determine the maximum dose of palbociclib given with re-induction chemotherapy in pediatric patients with relapsed B- or T-lineage ALL/LL.
Who can join the study?
This study might be a good fit for children and young adults who:
- Are between 12 months and 31 years old
- Have recurrent or refractory B- or T- lineage lymphoblastic leukemia and lymphoma
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or send us an email.